Moses Victor Javier Aguilar, Chief Research, Development & Innovation Officer at Procter & Gamble (PG), has demonstrated a clear selling bias in recent transactions, with $4.4 million in total sales outweighing $2.2 million in purchases across 28 filings. His activity has been exclusively concentrated in PG shares, with the most significant transaction occurring on February 13, 2026—a sale valued at $2.46 million alongside a smaller market purchase of $1.38 million the same day. Prior to this, Aguilar's December 3, 2025 filings showed a series of smaller transactions, including multiple sales ranging from $7,996 to $155,423, as well as acquisitions in similar amounts, suggesting potential portfolio rebalancing.
The pattern indicates Aguilar has been reducing his PG position, with no recent buys recorded—his last significant acquisition appears to have been in early December 2025. The majority of his transactions in late 2025 and early 2026 were sales, with the February 2026 disposal being the largest single trade by dollar value. Notably, multiple filings from mid-2025 through November 2025 reflect awards (code "A") with no reported value, likely representing equity grants or option exercises that did not involve direct purchases. The absence of new buy activity in recent months, combined with the substantial February 2026 sale, suggests a shift toward liquidity events rather than accumulation.
AI-assisted summary